Edition:
India

Lupin Ltd (LUPN.BO)

LUPN.BO on Bombay Stock Exchange

819.10INR
3:55pm IST
Change (% chg)

Rs7.40 (+0.91%)
Prev Close
Rs811.70
Open
Rs818.00
Day's High
Rs832.25
Day's Low
Rs814.95
Volume
134,650
Avg. Vol
145,552
52-wk High
Rs1,408.80
52-wk Low
Rs727.05

Chart for

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.05
Market Cap(Mil.): Rs469,414.59
Shares Outstanding(Mil.): 451.84
Dividend: 7.50
Yield (%): 0.72

Financials

  LUPN.BO Industry Sector
P/E (TTM): 23.14 30.95 32.74
EPS (TTM): 44.89 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-India's Lupin Gets FDA Nod For Generic Xenazine Tablets, 12.5 Mg And 25 Mg

* SAYS CO RECEIVES FDA APPROVAL FOR GENERIC XENAZINE TABLETS, 12.5 MG AND 25 MG Source text - http://bit.ly/2qUd2T4 Further company coverage:

23 Apr 2018

BRIEF-India's Lupin Gets Tentative U.S. FDA Nod For Generic Androgel, 1.62 Pct

* SAYS CO RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC ANDROGEL, 1.62 PERCENT Source text - https://bit.ly/2HEhHk8 Further company coverage:

17 Apr 2018

Sensex ends higher; Lupin gains

Indian indexes ended slightly higher on Friday, led by gains in stocks such as Lupin Ltd, but broader gains were capped as sentiment was subdued following U.S. President Donald Trump's proposal to impose more tariffs on China.

06 Apr 2018

Indian shares end higher; Lupin gains

April 6 Indian indexes ended slightly higher on Friday, led by gains in stocks such as Lupin Ltd, but broader gains were capped as sentiment was subdued following U.S. President Donald Trump's proposal to impose more tariffs on China.

06 Apr 2018

BRIEF-Lupin's Pithampur Unit 1 Facility Gets EIR From U.S. FDA

* SAYS PITHAMPUR UNIT 1 FACILITY RECEIVES ESTABLISHMENT INVESTIGATION REPORT (EIR) FROM US FDA

06 Apr 2018

MEDIA-India's Lupin to go for restructuring of its domestic business in FY19 - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

05 Apr 2018

BRIEF-Lupin's Goa Facility Completes Successful U.K MHRA Inspection

* SAYS CO'S GOA FACILITY COMPLETES SUCCESSFUL UK MHRA INSPECTION

03 Apr 2018

BRIEF-India's Lupin Says Pithampur Unit Cleared By Health Canada

* SAYS HEALTH CANADA MAINTAINED COMPLIANT RATING FOR UNIT 2 AT PITHAMPUR (INDORE) AND HAS ISSUED A REVISED ‘ESTABLISHMENT LICENSE’ Source text - https://bit.ly/2pW8cVF Further company coverage:

02 Apr 2018

BRIEF-Lupin Launches Generic Clobex Spray, 0.05 Pct In U.S.

* SPRAY IS USED FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS AFFECTING UP TO 20 PERCENT BODY SURFACE AREA IN PATIENTS 18 YEARS OF AGE OR OLDER Source text: http://bit.ly/2IeyRDQ Further company coverage:

29 Mar 2018

BRIEF-India's Lupin ‍​Gets FDA Nod For Generic Clobexa Spray, 0.05 Pct

* SAYS CO ‍​GETS FDA APPROVAL FOR GENERIC CLOBEXA SPRAY, 0.05% Source text - https://bit.ly/2Gg8Sf1 Further company coverage:

27 Mar 2018

Earnings vs. Estimates